# Boops Pets Launches Clinical Grade KSM 66 Ashwagandha Canine Calming Chews > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/nasc-audited-canine-calming-chews-ashwagandha/ > **Published:** 2026-04-08T04:02:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T14:02:24-04:00 > **Clinical Summary:** Discover NASC audited canine calming chews with KSM 66 Ashwagandha for pet anxiety. Quality control meets veterinary botanical supplements. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Veterinary MedicineAnxietyBotanical MedicineQuality ControlPet Supplements Why This Matters The veterinary cannabis and botanical supplement market operates with minimal regulatory oversight, creating quality and dosing uncertainties for pet owners seeking anxiety treatments. NASC auditing represents one of the few available quality standards in this space, though it doesn’t establish clinical efficacy. Clinical Summary Boops Pets has released ashwagandha-based calming chews for dogs that have undergone National Animal Supplement Council (NASC) auditing. Ashwagandha (Withania somnifera) has demonstrated stress-reducing properties in human studies through modulation of cortisol and GABA pathways, but veterinary-specific research remains limited. The NASC audit addresses manufacturing standards and label accuracy but does not validate therapeutic claims or establish species-appropriate dosing. Dr. Caplan’s Take “While ashwagandha shows promise for stress management, pet owners should understand that ‘clinical grade’ marketing doesn’t equal veterinary clinical validation. I’d want to see canine-specific pharmacokinetic and safety data before recommending any botanical intervention for pet anxiety.” Clinical Perspective 🧠 Veterinarians should counsel pet owners that NASC certification addresses quality control but not clinical effectiveness. Consider discussing evidence-based anxiety treatments first, and if owners pursue botanical supplements, recommend veterinary oversight for monitoring and potential drug interactions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Boops%20Pets%20Launches%20NASC%20Audited%20Clinical%20Grade%20KSM%2066%20Ashwagandha%20Canine%20Calmin...%20%40drcaplan&url=https%3A//www.petage.com/boops-pets-nasc-ashwagandha-canine-calming-chews/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.petage.com/boops-pets-nasc-ashwagandha-canine-calming-chews/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Boops%20Pets%20Launches%20NASC%20Audited%20Clinical%20Grade%20KSM%2066%20Ashwagandha%20Canine%20Calmin...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.petage.com/boops-pets-nasc-ashwagandha-canine-calming-chews/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.petage.com/boops-pets-nasc-ashwagandha-canine-calming-chews/](https://www.petage.com/boops-pets-nasc-ashwagandha-canine-calming-chews/) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis study?](#What_is_the_clinical_relevance_rating_of_this_cannabis_study) - [What medical areas does this cannabis research cover?](#What_medical_areas_does_this_cannabis_research_cover) - [Why is quality control mentioned as a key topic?](#Why_is_quality_control_mentioned_as_a_key_topic) - [How does this relate to veterinary medicine?](#How_does_this_relate_to_veterinary_medicine) - [What makes this cannabis news particularly noteworthy?](#What_makes_this_cannabis_news_particularly_noteworthy) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis study? This study has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating suggests the findings represent emerging developments or policy changes that warrant close monitoring by healthcare professionals. #### What medical areas does this cannabis research cover? The research spans multiple therapeutic areas including veterinary medicine, [anxiety treatment](https://cedclinic.com/benzodiazepine-discontinuation-rates-medical-cannabis/), and botanical medicine applications. These diverse applications highlight the broad potential medical uses of [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). #### Why is quality control mentioned as a key topic? Quality control is essential for cannabis-based medical products to ensure consistent dosing, purity, and therapeutic efficacy. Standardization helps establish reliable treatment protocols and ensures patient safety across different cannabis preparations. #### How does this relate to veterinary medicine? This research includes veterinary applications of cannabis, suggesting potential treatments for animals with conditions like anxiety or other medical issues. Veterinary [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) is an emerging field requiring specialized dosing and safety protocols for different animal species. #### What makes this cannabis news particularly noteworthy? The “Notable Clinical Interest” designation indicates this represents significant emerging findings or policy developments in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). These developments are considered important enough to monitor closely for potential impacts on [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Dog CBD Anxiety Gummies: What Pet Owners Need to Know Before Trying Them](https://cedclinic.com/medical-cannabis-ptsd-scoping-review/) Explore important considerations for using CBD gummies to manage dog anxiety, including safety and efficacy insights. [Learn More](https://cedclinic.com/medical-cannabis-ptsd-scoping-review/) [Flourish + Live Well's CBD Science Series CBD and Seizures in Dogs: What Science … – Instagram](https://cedclinic.com/a-new-hope-for-seizures-exploring-cbd-s-potential-for-dogs-with-epilepsy/) Review scientific findings on CBD use for seizures in dogs, highlighting veterinary perspectives and research updates. [Explore Research](https://cedclinic.com/a-new-hope-for-seizures-exploring-cbd-s-potential-for-dogs-with-epilepsy/) CBD Gummies News: What's Actually Worth Paying Attention To in 2026 Stay updated on the latest news and evidence regarding CBD gummies, including trends and clinical insights for 2026. Read Updates ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).